Entelos, Inc. (LSE: ENTL) announces that it has repurchased a total of 3.9 million shares of its common stock
(representing approximately 5.6% of its issued and outstanding common stock) at one pence per share.
    Entelos previously held no shares of its common stock in treasury, therefore, after reflecting this repurchase,
Entelos holds 3.9 million shares of common stock in treasury. Excluding the treasury shares, Entelos currently has
65,661,887 shares of common stock issued and outstanding.
     About Entelos 
    Entelos, Inc. ( www.entelos.com) is a US-based life sciences company applying next-generation predictive
technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its
proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and
more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of
personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical,
health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity,
diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.
    
    


Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Entelos Regs 차트를 더 보려면 여기를 클릭.
Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Entelos Regs 차트를 더 보려면 여기를 클릭.